Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

BACKGROUND: Vedolizumab, an anti‐α(4)β(7) integrin monoclonal antibody (mAb), is indicated for treating patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). As higher therapeutic mAb concentrations have been associated with greater efficacy in inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosario, M., Dirks, N. L., Gastonguay, M. R., Fasanmade, A. A., Wyant, T., Parikh, A., Sandborn, W. J., Feagan, B. G., Reinisch, W., Fox, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032981/
https://www.ncbi.nlm.nih.gov/pubmed/25996351
http://dx.doi.org/10.1111/apt.13243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032981/
https://www.ncbi.nlm.nih.gov/pubmed/25996351
http://dx.doi.org/10.1111/apt.13243

Ejemplares similares